Published : Sep-2019
No. of Pages : 162
1.1 List of Tables
1.2 List of Figures
2 Ovarian Cancer: Executive Summary
2.1 Double-Digit Growth Rate Expected for Ovarian Cancer Between 2018-2028
2.2 Drug Developers Expand Labels Through Novel Combinations and Broadening of Patient Eligibility
2.3 Unmet Need for More Effective Therapies in the Treatment-Resistant Disease Setting Will Largely Remain Unaddressed
2.4 An Individualized Treatment Paradigm Emerges for the First-Line Setting, While Targeted Therapies Are Struggling to Deliver for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors
5.3 Global and Historical Trends
5.3.1 7MM Trends in Diagnosed Incidence
5.3.2 7MM Trends in Observed Survival
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Ovarian Cancer (2018-2028)
5.5.1 Diagnosed Incident Cases of Ovarian Cancer
5.5.2 Age-Specific Diagnosed Incidence of Ovarian Cancer
5.5.3 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer
5.5.4 Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis
5.5.5 Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype
5.5.6 Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation
5.5.7 Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation
5.5.8 Diagnosed Incident Cases of Ovarian Cancer with HRD
5.5.9 Diagnosed Incident Cases of EOC with FR? Overexpression
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Improved Front-Line Therapies
7.3 Alternative Treatment Options for Platinum-Refractory/Resistant Patients
7.4 Individualized Treatment Approaches
7.5 Therapy Option for Histological Subtypes Beyond High-Grade Serous Ovarian Cancer
7.6 An Early-Stage Diagnostic for Ovarian Cancer
8 R&D Strategies
8.1 Overview
8.1.1 PARP Inhibitors Are Becoming a Focus of Clinical Development
8.1.2 Development of Companion Diagnostic and Robust Biomarker Platforms
8.1.3 Novel Mechanism of Action: Folate Receptor Alpha Targeting
8.1.4 Cell-Based Therapies at the Early Stages of Clinical Development
8.1.5 Platinum-Refractory Disease: Patients Might Have to Wait for Breakthrough Therapies
8.2 Clinical Trial Design
8.2.1 Current Clinical Trial Endpoints
8.2.2 Future Clinical Trial Endpoints
8.2.3 Moving Beyond the Current Platinum-Sensitive/Resistant Paradigm for Patient Recruitment in Clinical Trials
9 Pipeline Assessment
9.1 Overview
9.2 Innovative Early-Stage Approaches
9.3 Other Drugs in Development
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.3.1 Forecasting Methodology
11.3.2 Diagnosed Patients
11.3.3 Percent Drug-Treated Patients
11.3.4 Drugs Included in Each Therapeutic Class
11.3.5 Launch and Patent Expiry Dates
11.3.6 General Pricing Assumptions
11.3.7 Individual Drug Assumptions
11.3.8 Generic Erosion
11.3.9 Pricing of Pipeline Agents
11.4 Primary Research - KOLs Interviewed for This Report
11.5 Primary Research - Prescriber Survey
11.6 About the Authors
11.6.1 Analyst
11.6.2 Therapy Area Directors
11.6.3 Epidemiologist
11.6.4 Managing Epidemiologist
11.6.5 Global Director of Therapy Analysis and Epidemiology
11.6.6 Global Head and EVP of Healthcare Operations and Strategy
11.7 About GlobalData
11.8 Contact Us
11.9 Disclaimer
List of Tables
Table 1: Ovarian Cancer: Key Metrics in the 7MM
Table 2: FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum
Table 3: Risk Factors for Ovarian Cancer
Table 4: Treatment Guidelines for Ovarian Cancer, 2019
Table 5: Leading Treatments for Ovarian Cancer, 2019
Table 6: Potential Classification Systems for Recurrent Ovarian Cancer
Table 7: Comparison of Therapeutic Classes in Development for Ovarian Cancer, 2018-2028
Table 8: Innovative Early-Stage Approaches for Ovarian Cancer, 2019
Table 9: Other Drugs in Development for Ovarian Cancer, 2019
Table 10: Clinical Benchmark of Key Pipeline Immuno-oncology Drugs - Ovarian Cancer
Table 11: Clinical Benchmark of Key Pipeline Targeted Therapy Drugs - Ovarian Cancer
Table 12: Commercial Benchmark of Key Pipeline Immuno-oncology Drugs - Ovarian Cancer
Table 13: Commercial Benchmark of Key Pipeline Targeted Therapy Drugs - Ovarian Cancer
Table 14: Key Events Impacting Sales for Ovarian Cancer, 2018-2028
Table 15: Ovarian Cancer Market - Global Drivers and Barriers, 2018-2028
Table 16: Ovarian Cancer US Market - Drivers and Barriers, 2018-2028
Table 17: Ovarian Cancer 5EU Market - Drivers and Barriers, 2018-2028
Table 18: Ovarian Cancer Japan Market - Drivers and Barriers, 2018-2028
Table 19: Key Historical and Projected Launch Dates for Ovarian Cancer
Table 20: Key Historical and Projected Patent Expiry Dates for Ovarian Cancer
Table 21: Average Body BSA Across the 7MM
Table 22: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for Ovarian Cancer in 2018 and 2028
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Avastin in Combination with Paclitaxel + Carboplatin
Figure 3: Diagnosed Incidence of Ovarian Cancer, 7MM, Women, Ages ?18 Years, 2008-2028, Cases per 100,000 Population
Figure 4: Sources Used and Not Used for Diagnosed Incident Cases of Ovarian Cancer
Figure 5: Sources Used for Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis
Figure 6: Sources Used for Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype
Figure 7: Sources Used for Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation
Figure 8: Sources Used for Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation
Figure 9: Sources Used for Diagnosed Incident Cases of Ovarian Cancer with HRD
Figure 10: Sources Used for EOC Cases with FR? Overexpression
Figure 11: Diagnosed Incident Cases of Ovarian Cancer, 7MM, Women, Ages ?18 Years, 2018
Figure 12: Age-Specific Diagnosed Incident Cases of Ovarian Cancer, 7MM, Women, Ages ?18 Years, 2018
Figure 13: Five-Year Diagnosed Prevalent Cases of Ovarian Cancer, 7MM, Women, Ages ?18 Years, 2018, N
Figure 14: Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis, 7MM, Women, Ages ?18 Years, 2018, N
Figure 15: Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype, 7MM, Women, Ages ?18 Years, 2018, N
Figure 16: Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation, 7MM, Women, Ages ?18 Years, 2018, N
Figure 17: Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation, 7MM, Women, Ages ?18 Years, 2018, N
Figure 18: Diagnosed Incident Cases of Ovarian Cancer with HRD, 7MM, Women, Ages ?18 Years, 2018, N
Figure 19: Diagnosed Incident Cases of EOC with FR? Overexpression, 7MM, Women, Ages ?18 Years, 2018, N
Figure 20: Top-Level Treatment Flow Chart for Ovarian Cancer Patients
Figure 21: Unmet Needs and Opportunities in Ovarian Cancer
Figure 22: Overview of the Development Pipeline in Ovarian Cancer
Figure 23: Key Phase II/III Trials for IO Agents in Ovarian Cancer Pipeline in the 7MM, 2019
Figure 24: Key Phase II/III Trials for Targeted Therapy Agents in Ovarian Cancer Pipeline in the 7MM, 2019
Figure 25: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Avastin + Chemotherapy
Figure 26: Global (7MM) Sales Forecast by Country for Ovarian Cancer in 2018 and 2028
Figure 27: Global Sales Forecast by Class for Ovarian Cancer in 2018 and 2028
Figure 28: Sales Forecast by Class for Ovarian Cancer in the US in 2018 and 2028
Figure 29: Sales Forecast by Class for Ovarian Cancer in the 5EU in 2018 and 2028
Figure 30: Sales Forecast by Class for Ovarian Cancer in Japan in 2018 and 2028
